文献速递生殖医学

缩宫素拮抗剂诺拉西班在辅助生殖中的作用机制

The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers.
PubMed 文献 · Reprod Biomed Online · 2021-01-16

两种剂量均降低子宫收缩频率并增加内膜血流灌注,1800 mg组有10个内膜基因差异表达,提示更高剂量效应更明显。

要点

  • 诺拉西班可降低子宫收缩频率并增加内膜血流灌注。
  • 1800 mg组10个内膜基因差异表达,部分与着床窗口和内膜容受性相关。
  • 1800 mg效应较900 mg更明显,支持在IVF患者中测试更高剂量。

核心结论

  • 诺拉西班可能通过降低子宫收缩频率、增加内膜灌注及调控内膜基因表达来提高胚胎移植后妊娠率。
  • 1800 mg诺拉西班的效应较900 mg更明显。

研究设计与样本

  • 在相当于囊胚移植日给予安慰剂、900 mg或1800 mg诺拉西班。
  • 采用超声评估子宫收缩频率和内膜灌注,内膜活检行下一代测序。

主要发现

  • 两种剂量诺拉西班均显示子宫收缩频率降低和内膜灌注增加,且取决于评估时间点。
  • 1800 mg组10个内膜基因显著差异表达(校正P < 0.05):DPP4、CNTNAP3、CNTN4、CXCL12、TNXB、CTSE、OLFM4、KRT5、KRT6A、IDO2。
  • OLFM4、DPP4和CXCL12的调控方向与着床窗口期参与着床的基因一致。
  • DPP4、CXCL12和IDO2与蜕膜化和内膜容受性相关。

临床怎么用

  • 诺拉西班可能作为改善胚胎移植结局的候选药物,1800 mg剂量值得在IVF患者中进一步研究。

局限性

  • 研究在健康绝经前女性中进行,非IVF患者人群。
  • 样本量有限,为机制性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: What are the effects of the oxytocin receptor (OTR) antagonist nolasiban on uterine contractions, endometrial perfusion and endometrial mRNA expression? DESIGN: Randomized, double-blind, parallel-group, mechanism-of-action study with nolasiban. Forty-five healthy, pre-menopausal women were treated with placebo, 900 mg or 1800 mg nolasiban on the day corresponding to blastocyst transfer. Ultrasonographic uterine contraction frequency and endometrial perfusion were assessed, and endometrial biopsies analysed by next-generation sequencing. RESULTS: Both doses of nolasiban showed decreased contraction frequency and increased endometrial perfusion depending on the time point assessed. At 1800 mg, 10 endometrial genes (DPP4, CNTNAP3, CNTN4, CXCL12, TNXB, CTSE, OLFM4, KRT5, KRT6A, IDO2) were significantly differentially expressed (adjusted P < 0.05). Of these, OLFM4, DPP4 and CXCL12 were regulated in the same direction as genes involved in implantation during the window of implantation. In addition, three genes (DPP4, CXCL12 and IDO2) were associated with decidualization and endometrial receptivity. CONCLUSIONS: These data expand our knowledge of the mechanism of action of nolasiban in increasing pregnancy rates after embryo transfer. The results suggest more marked effects of nolasiban 1800 mg compared with the 900 mg dose, supporting testing at higher doses in IVF patients.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Pierzyński P, Pohl O, Marchand L, et al. The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers. Reprod Biomed Online. 2021. PMID: 34167897. doi:10.1016/j.rbmo.2021.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。